Improving Compliance with Low Dose Acetylsalicyclic Acid (ASA)-New Insights

August 28, 2011

Venue: ESC Congress 2011 – Paris / France,
Time: 12:45-13:30
Course Director: Prof. Karl Swedberg

1 CME credit

Learning objectives:

  • To reinforce the importance of long-term low-dose acetylsalicylic acid (ASA) treatment for the prevention of thrombotic cardiovascular (CV) events in high-risk CV patients.
  • To describe the adverse impact of low-dose ASA discontinuation on cardiovascular and cerebrovascular outcomes in the secondary prevention of cardiovascular disease.
  • To highlight the gastrointestinal (GI) risks associated with low-dose ASA therapy, and their potential effects on ASA discontinuation.
  • To evaluate options for managing GI risk in patients requiring antiplatelet therapy for prevention of thrombotic CV events in high-risk CV patients.

Target audience

Trained Cardiologists, Haematologists, Diabetologists, Pharmacists, Primary Care Physicians, Research Scientists.

Return to eventlist